| Author | Espíndola, Otávio Melo | |
| Author | Fuller, Trevon L. | |
| Author | Araújo, Mia Ferreira de | |
| Author | Tort, Luis Fernando Lopez | |
| Author | Guaraldo, Lusiele | |
| Author | Calvet, Guilherme | |
| Author | Resende, Paola | |
| Author | Bonaldo, Myrna | |
| Author | Whitworth, Jimmy | |
| Author | Smith, Chris | |
| Author | Siqueira, Marilda | |
| Author | Brasil, Patrícia | |
| Access date | 2023-08-25T23:00:42Z | |
| Available date | 2023-08-25T23:00:42Z | |
| Document date | 2023 | |
| Citation | ESPÍNDOLA, Otávio Melo et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Scientific Reports, v. 13, p. 1-7, May 2023. | en_US |
| ISSN | 2045-2322 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/60233 | |
| Description | A Rede Genômica Fiocruz é formada por especialistas de todas as unidades da Fundação no país e de institutos parceiros que se empenham diariamente em gerar dados mais robustos sobre o comportamento do SARS-Cov-2 e contribuir para um melhor preparo do país no enfrentamento da pandemia em termos de diagnóstico mais precisos e vacinas eficazes. Saiba mais sobre a Rede Genômica Fiocruz em: http://www.genomahcov.fiocruz.br/ | |
| Sponsorship | UK Research and Innovation MR/V033530/1, Conselho Nacional de Desenvolvimento Científco e Tecnológico PQ 311562/2021-3; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro COVID: E-26/210.146/2020, EMERGENTES: 26/211.565/2019, and CNE: E-26/200.935/2022; Unidade de Apoio ao Diagnóstico da Covid-19 (UNADIG-RJ); Fiocruz Vice-Presidência de Produção e Inovação em Saúde (VPPIS); Labi Exames | en_US |
| Language | eng | en_US |
| Publisher | Nature Publishing Group | en_US |
| Rights | open access | |
| Title | Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting | en_US |
| Type | Article | |
| DOI | 10.1038/s41598-023-34035-9 | |
| Abstract | COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Institute of the Environment and Sustainability. University of California Los Angeles. Los Angeles, USA. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil / Laboratory of Molecular Virology. Biological Sciences Department. Universidad de la República. Salto, Uruguay. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Molecular Biology. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Department of Clinical Research. London School of Hygiene and Tropical Medicine. London, WC1E 7HT, UK. | en_US |
| Affilliation | Department of Clinical Research. London School of Hygiene and Tropical Medicine. London, WC1E 7HT, UK. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Subject | COVID-19 | en_US |
| Subject | Omicron variant | en_US |
| Subject | Complete vaccination | en_US |
| Subject | BNT162b2 | en_US |
| Subject | ChAdOx1 | en_US |
| Subject | CoronaVac | en_US |
| Subject | Vaccine | en_US |
| e-ISSN | 2045-2322 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
